RxDoctor Payments Data

Abraham John, MD

Family Medicine · Pasadena, TXNPI 1184707887

Payments from drug & device makers

$417in general payments, 2019–2025

Across 28 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$210
  • Amarin Pharma, Inc.$118
  • Teva Pharmaceuticals USA, Inc.$21
  • Merz Pharmaceuticals, LLC$16
  • Pfizer$15
  • Dexcom, Inc.$14
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$27365%
  • Education$14535%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$417 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$396,843
Medicare patients
649
Services billed
10,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide285$353,242
EliquisApixaban239$276,927
JardianceEmpagliflozin161$221,582
MounjaroTirzepatide150$213,152
FarxigaDapagliflozin Propanediol199$181,352
Trelegy ElliptaFluticasone/Umeclidin/Vilanter108$93,391
TrulicityDulaglutide62$77,491
XareltoRivaroxaban63$76,075
JanuviaSitagliptin Phosphate54$57,490
LinzessLinaclotide57$57,483
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog64$51,137
TradjentaLinagliptin56$49,655
MyrbetriqMirabegron43$42,929
ProliaDenosumab24$40,672
Tresiba Flextouch U-200Insulin Degludec24$40,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12$290,643212 claims
PfizerEliquis$15$276,927239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →